Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin
Author:
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2009.07715.x/fullpdf
Reference7 articles.
1. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura;Arnold;Annals of Internal Medicine,2007
2. B cell depletion therapy in rheumatic disease;Edwards;Best practice & research. Clinical Rheumatology,2006
3. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study;Godeau;Blood,2008
4. Enteroviral meningoencephalitis in a patient with non-Hodgkin’s lymphoma treated previously with rituximab;Padate;Clinical and Laboratory Haematology,2006
5. Long-term follow-up analysis after rituximab therapy in children with refractory symptomatic ITP: identification of factors predictive of a sustained response;Parodi;British Journal of Haematology,2009
Cited by 81 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Long-Lasting SARS-CoV-2 Infection With Post-COVID-19 Chronic Interstitial Pneumonia in a Patient With Chronic Lymphocytic Leukemia Treated Successfully With Intravenous Immunoglobulin;Cureus;2024-01-08
2. Pathogenesis and management of immune dysfunction secondary to B cell haematological malignancies;Internal Medicine Journal;2023-12-08
3. Clinical Course and Outcomes of COVID-19 Infection in Patients Treated with Rituximab: A Tertiary Care Center Experience;Open Access Rheumatology: Research and Reviews;2023-08
4. Case report: Synergistic defects of CASP10 and BTK leading to autoimmune lymphoproliferative syndrome type IIa, complicated by severe hemophagocytic lymphohistiocytosis;Immunologic Research;2023-04-17
5. Acquired B-cell deficiency secondary to B-cell-depleting therapies;Journal of Immunological Methods;2022-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3